Evidence map›Paper›PMID 18388178›Full record

ArticleBlood2008

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Michael J Borowitz, Meenakshi Devidas, Stephen P Hunger, W Paul Bowman, Andrew J Carroll, William L Carroll, Stephen Linda, Paul L Martin, D Jeanette Pullen, David Viswanatha and 4 more

5 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 377 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
377citing papers in PubMed, 1 pooled it
42.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00005585 phase3completednot on this map

ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study

TypeinterventionalSponsorChildren's Oncology GroupRan2000Enrolled838ConditionsLeukemiaArmscyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium
NCT00005596 phase3completednot on this map

ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study

TypeinterventionalSponsorChildren's Oncology GroupRan2000 to 2007Enrolled1,076ConditionsLeukemiaArmscyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium
NCT00005603 phase3completednot on this map

ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study

TypeinterventionalSponsorChildren's Oncology GroupRan2000Enrolled276ConditionsLeukemiaArmsasparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone
NCT04562792 phase2completednot on this mapstarted 2020, after this paper: background citation

A Pilot Study of Targeted Daunorubicin Dosing to Overcome Chemotherapeutic Resistance in Children With Relapsed or Refractory Acute Leukemia

TypeinterventionalSponsorChildren's Mercy Hospital Kansas CityRan2020 to 2022Enrolled1ConditionsRelapsed Pediatric ALL, Relapsed Pediatric AML, Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic LeukemiaArmsDaunorubicin
NCT06846294 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

OBesity PREVention in Children and Young People Treated with ALLtogetheR: Prehabilitation Feasibility Intervention

TypeinterventionalSponsorUniversity of ExeterRan2025 to 2029Enrolled90ConditionsDiet Intervention, Physical Activity Intervention, Standard Care ControlArmsDiet, Diet and physical activity
3 · Its place in the literature

Who cites it

377 citing papers in PubMed, 1 synthesis or guideline pooled it, 828 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  19. Flow Cytometric Immunophenotyping of Acute Lymphoblastic Leukemia.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  20. Article

317 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 1 country.

Michael J BorowitzDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. mborowit@jhmi.edu
Meenakshi Devidas
Stephen P Hunger
W Paul Bowman
Andrew J Carroll
William L Carroll
Stephen Linda
Paul L Martin
D Jeanette Pullen
David Viswanatha
Cheryl L Willman
Naomi Winick
Bruce M Camitta
Children's Oncology Group
University of Florida · USCook Children's Medical Center · USDuke University · USJohns Hopkins University · USMayo Clinic · USMayo Clinic in Arizona · USMedical College of Wisconsin · USNew York University · USThe University of Texas Southwestern Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Colorado Denver · USUniversity of New Mexico · US

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
RESIDUAL DISEASE DETECTION IN ALL USING FLOW CYTOMETRYR01CA086011 · NCI · JOHNS HOPKINS UNIVERSITY · PI BOROWITZ, MICHAEL J · 2000 to 2010
$4.2M
NCI NIH HHS R01 CA086011NCI NIH HHS R01 CA86011NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA98543
6 · The paper itself

Abstract

Minimal residual disease (MRD) is an important predictor of relapse in acute lymphoblastic leukemia (ALL), but its relationship to other prognostic variables has not been fully assessed. The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with precursor B-cell ALL (B-ALL). The presence of MRD in day-8 blood and day-29 marrow MRD was associated with shorter event-free survival (EFS) in all risk groups; even patients with 0.01% to 0.1% day-29 MRD had poor outcome compared with patients negative for MRD patients (59% +/- 5% vs 88% +/- 1% 5-year EFS). Presence of good prognostic markers TEL-AML1 or trisomies of chromosomes 4 and 10 still provided additional prognostic information, but not in National Cancer Institute high-risk (NCI HR) patients who were MRD(+). The few patients with detectable MRD at end of consolidation fared especially poorly, with only a 43% plus or minus 7% 5-year EFS. Day-29 marrow MRD was the most important prognostic variable in multi-variate analysis. The 12% of patients with all favorable risk factors, including NCI risk group, genetics, and absence of days 8 and 29 MRD, had a 97% plus or minus 1% 5-year EFS with nonintensive therapy. These studies are registered at www.clinicaltrials.gov as NCT00005585, NCT00005596, and NCT00005603.

Indexed as

Biomarkers, TumorBone MarrowChildClinical Trials as TopicCore Binding Factor Alpha 2 SubunitDisease-Free SurvivalETS Translocation Variant 6 ProteinHumansMultivariate AnalysisNeoplasm, ResidualOncogene Proteins, FusionPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisProportional Hazards ModelsRecurrenceRisk FactorsBiomarkers, TumorCore Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinOncogene Proteins, FusionTEL-AML1 fusion protein

Identifiers

PMID18388178
PMCPMC2424148
OpenAlexW2075139424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.